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ABSTRACT 1 
Background: Denatonium benzoate (DB) has been shown to influence ongoing ingestive 2 
behavior and gut peptide secretion.  3 
Objectives: To study the effect of intragastric administration of DB on interdigestive motility, 4 
motilin and ghrelin plasma levels, hunger and satiety ratings and food intake in healthy 5 
volunteers. 6 
Design: Lingual bitter taste sensitivity was tested using 6 concentrations of DB in 65 subjects. 7 
Placebo or DB (1 µmol/kg) were given intragastrically to assess their effect on fasting 8 
gastrointestinal motility and hunger ratings; on motilin and ghrelin plasma levels; on satiety 9 
and finally on caloric intake. 10 
Results: Women (n=39) were more sensitive towards a lingual bitter stimulus (p=0.005) than 11 
men (n=26). In women (n=10), intragastric DB caused a switch in the origin of phase III 12 
contractions from stomach to duodenum (p=0.001) and decreased hunger ratings (p=0.04). 13 
These effects were not observed in male participants (n=10). In females (n=12), motilin 14 
(p=0.04) plasma levels decreased after intragastric DB administration while total and 15 
octanoylated ghrelin were not affected. Intragastric administration of DB decreased hunger 16 
(p=0.008) and increased satiety ratings (p=0.01) after a meal (500 kcal) in 13 female subjects 17 
without affecting gastric emptying in 6 female subjects. Caloric intake tended to decrease 18 
after DB administration compared to placebo (720±58 kcal vs 796±45 kcal; p=0.08) in 20 19 
female subjects. 20 
Conclusions: Intragastric DB administration decreases both antral motility and hunger ratings 21 
during the fasting state, possibly due to a decrease in motilin release. Moreover, DB decreases 22 
hunger and increases satiety ratings after a meal and shows potential to decrease caloric 23 
intake. This trial was registered at clinicaltrials.gov as NCT02759926. 24 
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INTRODUCTION  28 
Denatonium benzoate (DB), benzyl-diethyl (2:6-xylylcarbamoyl methyl) ammonium benzoate, 29 
is a strong bitter tastant added to household products to prevent ingestion of potentially 30 
harmful substances through taste aversion (1, 2). Concentrations as low as 10 ppb are already 31 
detectable, at 50 ppb the taste is distinguishably bitter and at 10 ppm it is described as 32 
unpleasantly bitter. In the US, DB is added at a concentration of 6 ppm to denature alcohol 33 
(3). Specialized G-protein coupled receptors (GPCRs) from the taste 2 receptor (TAS2R) family 34 
are involved in the perception of bitter compounds (4). Until now, 25 TAS2Rs have been 35 
identified in humans (5). Based on the sensitivity towards 6-n-propylthiouracil (PROP), three 36 
categories of bitter sensitivity have been identified: non-tasters, medium-tasters and super-37 
tasters (6, 7). It has been reported that more women than men are classified as super-tasters 38 
(6, 8). 39 
Besides its extreme bitter taste, DB also has effects on gastrointestinal functions. Direct 40 
intraluminal administration of DB in mice has shown to inhibit ongoing ingestive behavior, to 41 
suppress food intake and to inhibit gastric emptying (9, 10). Moreover, DB stimulated the in 42 
vitro release of glucagon-like peptide 1 (GLP-1) and cholecystokinin (CCK), which are known 43 
to increase satiety and satiation respectively (11, 12). Intragastric administration of DB in 44 
humans has been shown to impair relaxation of the proximal stomach after infusion of a liquid 45 
meal and to increase satiation during an oral nutrient tolerance test (13). 46 
During the fasting state, the gastrointestinal tract (GIT) exhibits a specific contractility pattern 47 
known as the migrating motor complex (MMC), which can be divided into three phases (14-48 
17). During phase I, no contractions are present in the upper GIT; activity increases during 49 
phase II to reach a burst of maximum contractility during phase III, which can originate from 50 
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the stomach or the small intestine (14, 15). Exogenous administration of motilin or ghrelin 51 
triggers a premature gastric phase III in healthy volunteers (17, 18). Endogenous motilin 52 
plasma levels, but not ghrelin, fluctuate in synchrony with antral contractility of the MMC, to 53 
reach a peak just before the occurrence of a gastric phase III (16, 17, 19). We recently showed 54 
that motilin-induced gastric phase III contractions of the MMC signal hunger in healthy 55 
volunteers and that motilin plasma levels were closely associated with interdigestive hunger 56 
ratings (20, 21). In 1916, Carlson (22) reported an inhibitory effect of intragastrically 57 
administered bitter compounds on both fasting gastric contractility and hunger sensations, 58 
but the underlying mechanism was not elucidated. 59 
A first objective of the current study was to evaluate gender differences in the bitter taste 60 
sensation of orally administered DB in healthy volunteers. Secondly the effect of intragastric 61 
administration of DB on hunger ratings and gastrointestinal activity was evaluated. The third 62 
aim was to evaluate the role of gastrointestinal hormones in the DB-induced effects. As fourth 63 
and fifth objectives, we evaluated if DB was able to attenuate the return of hunger after a 64 
standardized meal and to decrease caloric intake respectively.  65 
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MATERIAL AND METHODS  66 
This study was approved by the Medical Ethics Committee of the Leuven University Hospital, 67 
Leuven, Belgium, and performed in full accordance with the Declaration of Helsinki. 68 
Study design 69 
The current study consisted of 5 independent protocols studying the following parameters: 70 
lingual bitter taste sensitivity, gastrointestinal activity, hormonal responses, satiety ratings 71 
and food intake. 72 
Test compounds 73 
DB was purchased from Sigma-Aldrich (St Louis, MO, USA). Solutions of DB were prepared in 74 
tap water. The stock concentration for intragastric administration was 10 mM. A volume of 75 
0.1 ml/kg bodyweight was administered. The dosage of DB was chosen based on its inhibitory 76 
effect on gastric accommodation in healthy volunteers (13). Tap water was given during the 77 
placebo condition in a volume of 0.1 ml/kg bodyweight. The pH between the 2 test solutions 78 
did not differ (pH7.4). 79 
Subjects 80 
Volunteers were eligible to participate if they were healthy, aged between 18 and 60 years 81 
old, had a BMI (in kg/m²) between 18 and 30, and were recruited from an existing volunteer 82 
database in our group. Exclusion criteria were gastrointestinal diseases, abdominal surgery 83 
(appendectomy allowed), psychiatric illnesses, and usage of drugs affecting the GIT or central 84 
nervous system. Written informed consent was obtained from all volunteers before the start 85 
of the study. A total of 65 volunteers (40% men; mean±SEM age: 29±1 y; mean±SEM BMI: 86 
23±0.4) participated in the bitter taste protocol; 20 (50% men; age: 27±9 y; BMI: 24±2) 87 
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participated in the gastrointestinal protocol; 12 female subjects (age: 31±4 y; BMI: 22±1) 88 
participated in the hormone protocol; 13 female subjects (age: 28±3 y; BMI: 23±1) participated 89 
in the satiety protocol and 20 female (age: 23±0.3 y; BMI: 22±1) subjects were included in the 90 
food intake protocol. Sample sizes were calculated based on results from previous studies and 91 
provided 80% power to detect significant differences of 15% with an alfpha of 0.05 (13, 23, 92 
24). Based on the results obtained from the lingual (study 1) and gastrointestinal (study 2) 93 
bitter sensitivity studies it was decided to only include female participants for the last 3 study 94 
protocols. A flow chart of the subject distribution can be found in the online supplemental 95 
material (Supplemental Figure 1). None of the volunteers dropped out. Volunteers that 96 
participated in multiple protocols were randomly selected. All subjects were studied after an 97 
overnight fast of 12 hours and were asked to refrain from smoking at least 1 hour before the 98 
start of the study except for the first study protocol where smoking was not allowed before 99 
the start of the study. 100 
Study protocols 101 
Study 1: Bitter taste sensitivity of DB 102 
Six different concentrations (0, 0.1 µM, 1 µM, 10 µM, 0.1 mM and 1 mM) of DB were tested 103 
using taste strips (25). The taste strips were placed on the tongue for 90 sec with a closed 104 
mouth. Between each concentration participants rinsed their mouth with tap water. The taste 105 
strips were given in ascending order of DB concentration, but participants were not aware of 106 
this. Bitter taste sensation was scored for each concentration on a 10 cm visual analogue scale 107 
(VAS) (0 cm: not bitter at all, 10 cm: extremely bitter).  108 
Study 2: Hunger and gastrointestinal motility responses to intragastric DB administration 109 
during the interdigestive state 110 
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This study was a placebo-controlled single-blind randomized trial. All these participants also 111 
participated in study 1 (Supplemental Figure 1). Placebo (tap water) or DB (1 µmol/kg 112 
bodyweight) was administered directly into the upper part of the stomach through a 113 
nasogastric feeding tube (Flocare, Nutricia, Bornem, Belgium), 20 min after a complete MMC 114 
cycle (Figure 1A). The position of the feeding tube was checked with fluoroscopy. By bypassing 115 
the tongue, participants could not taste which compound was given. After administration, the 116 
measurement continued until the next phase III. Hunger was scored every 5 min on a 10 cm 117 
VAS (0 cm: not at all hungry, 10 cm: as hungry as I have ever felt) (26). Adverse events 118 
(headache, nausea and stomach ache) were scored every 20 min on a 9-point numerical rating 119 
scale. 120 
Study 3: The effect of intragastric DB administration on motilin and ghrelin plasma levels 121 
during the interdigestive state 122 
This study was a placebo-controlled single-blind randomized trial. These subjects also 123 
participated in study 1 and 10 of them also participated in study 2 (Supplemental Figure 1). 124 
Twenty minutes (Figure 1B) after the end of a phase III contraction either placebo (tap water) 125 
or DB (1 µmol/kg bodyweight) were administered directly into the upper part of the stomach 126 
through a nasogastric feeding tube. The position of the feeding tube was checked with 127 
fluoroscopy. The measurement was continued for another 2 hours and blood samples were 128 
taken every 10 min to measure motilin and ghrelin plasma levels. The first blood sample was 129 
taken 10 min prior to intragastric administration. Hunger was scored every 5 min on a VAS. 130 
Study 4: The effect of DB on hunger and satiety ratings after a meal 131 
This study was a placebo-controlled single-blind randomized trial. Thirty minutes (Figure 1C) 132 
after the intragastric administration of placebo (tap water) or DB (1 µmol/kg bodyweight), a 133 
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meal, consisting of two pancakes (500 kcal total), was consumed within 15 min. In 6 subjects 134 
(31±6 years, 23±2 kg/m²), pancakes ingested on both occasions were labeled with sodium 13C-135 
octanoate. Every 15 min, starting from just before the treatment until 6 hours after the meal, 136 
volunteers exhaled in an exetainer that was stored in the fridge for later analysis. The 13CO2 137 
secretion data was analyzed by non-linear regression to allow curve fitting and calculation of 138 
the gastric half-emptying time. Subjects scored their hunger and satiety feelings prior to the 139 
administration and every 15 min for 4 hours starting from the meal intake on a VAS. 140 
Study 5: The effect of DB on food intake 141 
This study was a placebo-controlled double-blind randomized trial. Forty minutes after the 142 
intragastric administration of DB (1 µmol/kg bodyweight) or placebo (tap water), subjects ate 143 
ad libitum from an excess free-choice buffet for 1 hour. Food items included a variety of pre-144 
sliced, ready-to-eat food items including bread, ham, cheese, lettuce, tomato, mayonnaise, 145 
jam, sweets, crisps, rice pudding, waffles, chocolate, apple and banana, which were weighed 146 
pre- and postprandially to calculate caloric intake. The total caloric value of the buffet meal 147 
was 2330 kcal containing 55 g protein, 94 g fat of which 32 g was saturated and 291 g 148 
carbohydrates. 149 
Study techniques 150 
Antroduodenal motility: 151 
Activity of the MMC was measured in study protocol 2 and 3 using a high-resolution solid-152 
state manometry catheter (36 channels, spaced 1 cm apart, Manoscan 360, Sierra Scientific 153 
Instruments, Los Angeles, CA, USA, Manoview analysis software v2.0.) as described previously 154 
(19). During the manometry measurements, phases of the MMC were identified based on 155 
10 
 
 
 
standardized definitions (27, 28). Motility index (MI) was calculated as follows: (number of 156 
contractions*average amplitude contractions*average duration contractions)/5min (19, 29). 157 
Average MI was calculated by averaging 6 consecutive antral channels. The anatomical 158 
location of the channels was determined via fluoroscopy and through the characteristics of 159 
the contractions measured using high-resolution manometry.  160 
Hormone measurements: 161 
Blood samples for motilin detection were collected in lithium heparin tubes containing 500 162 
kIU/ml aprotinin (Roche Applied Science, Penzberg, Germany) and stored at -80°C, after 163 
centrifugation, until assayed. Ghrelin blood samples were collected in EDTA tubes 164 
supplemented with 500 kIU/ml aprotinin, centrifuged, acidified to a final concentration of 165 
0.1N HCl, extracted on Sep-Pak C18 columns and vacuum-dried. Motilin and ghrelin levels 166 
were determined by radioimmunoassay as fully described elsewhere (10, 19). 167 
Statistical analysis 168 
Significance was set at p<0.05. BMI and age were compared between sexes using two-tailed 169 
unpaired Student’s t-tests or Mann Whitney U tests depending on the distribution. Bonferroni 170 
correction for multiple testing was applied for post-hoc t-tests. SAS (Statistical Analysis System 171 
version 9.3; SAS Institute) was used to analyze the data. Data are represented as mean±SEM 172 
or median [Q1, Q3]. 173 
Study 1: Bitter taste sensitivity of DB 174 
Bitter taste sensitivity was analyzed using mixed models with BMI, sex, DB concentration and 175 
an interaction effect between sex and DB concentration as independent variables. Sex and DB 176 
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concentration were entered as categorical variables. DB concentration was entered as a 177 
repeated within-subject variable.  178 
Study 2: Hunger and gastrointestinal motility responses to intragastric DB administration 179 
during the interdigestive state 180 
The percentage origin of phase III was compared between placebo and DB with McNemar’s 181 
test. Paired Student’s t-tests were used to compare the interval between administration and 182 
phase III contractions between placebo and DB. Percentage change of hunger was calculated 183 
with 10 min before intragastric administration as the reference point. Mixed model analysis 184 
was used to compare percentage change of hunger between placebo and DB during phase III. 185 
Drug (placebo and DB) and time were entered as categorical fixed effects; a drug-by-time 186 
interaction effect was included. Drug and time were entered as within-subject variables. 187 
Study 3: The effect of intragastric DB administration on motilin and ghrelin plasma levels 188 
during the interdigestive state 189 
Mixed model analysis was used to assess the main effects of time and drug (placebo and DB) 190 
and the interaction effect between time and drug on the percentage change of hormone 191 
plasma levels. Drug and time were entered as within-subject categorical variables. Percentage 192 
change of hormone plasma levels was calculated with 10 min prior to intragastric 193 
administration as the reference point. 194 
The effect of hormone plasma levels on MI antrum was assessed using mixed model analysis 195 
with the hormone of interest (motilin, total ghrelin or octanoylated ghrelin), drug (placebo 196 
and DB) and time as main effects together with an interaction effect between drug and 197 
hormone. Drug and time were entered as categorical within-subject variables. The same 198 
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analysis was done for hunger as the dependent variable. Percentage change was used for MI 199 
antrum, hormone plasma levels and hunger. The reference point was set at 10 min prior to 200 
intragastric administration. 201 
Study 4: The effect of DB on the return of hunger after a meal 202 
Mixed model analysis was used to assess the effect of drug (placebo and DB) on hunger and 203 
satiety after a meal intake. Drug and time were included as categorical within-subject main 204 
effects together with their interaction effect. Gastric half-time emptying time was compared 205 
between the 2 conditions using Wilcoxon signed rank test. 206 
Study 5: The effect of DB on food intake 207 
Our hypothesis for this protocol was that intragastric administration of DB would decrease 208 
caloric intake compared to placebo. This hypothesis was formulated based on the results of 209 
our previous experiments which are described in the results section (study 2-4). Based on the 210 
hypothesized direction of the effect we decided to compare caloric intake between placebo 211 
and DB administration using a one-tailed paired Student’s t-test.    212 
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RESULTS  213 
Women are more sensitive to DB lingual stimulation than men 214 
BMI (p=0.02), but not age (p=0.9), differed between the two sexes (Table 1). Increasing 215 
concentrations of DB were perceived as more bitter (Figure 2; p<0.0001), but a significant sex 216 
effect (Figure 2; p=0.005) was also present. There was no interaction effect between sex and 217 
DB concentration (p=0.1). There was a trend of a positive association between BMI and bitter 218 
taste perception (beta coefficient of 0.3±0.2; p=0.06). 219 
Intragastric administration of DB inhibits gastric phase III and decreases hunger scores in 220 
female participants 221 
BMI (p=0.003), but not age (p=0.6), differed between the two sexes (Table 1). None of the 222 
volunteers could discriminate between placebo and DB during intragastric administration. No 223 
adverse events were reported by any of the participants when DB was given. 224 
In women, administration of DB (Figure 3A; p=0.001) reduced the number of phase III 225 
contractions with a gastric origin from 67% (placebo) to 33% (DB). The interval between 226 
intragastric administration and the occurrence of phase III did not differ (p=0.5) between 227 
placebo (76±12 min) and DB (93±12 min) treatment. In men (Figure 3B) there was no (p=0.1) 228 
difference in the origin of phase III contractions between placebo (57% gastric) and DB (40% 229 
gastric). The interval between intragastric administration and the occurrence of phase III did 230 
not differ (p=0.2) between placebo (76±11 min) and DB (111±19 min). 231 
The switch from a gastric to a duodenal phase III origin in females after DB administration was 232 
accompanied by a significantly lower percentage change of hunger scores compared to 233 
14 
 
 
 
placebo (Figure 3C; p=0.04). In contrast, in male participants, the percentage change in hunger 234 
scores (Figure 3D; p=0.3) during phase III did not differ between placebo and DB treatment.  235 
Intragastric administration of DB inhibits the increase in motilin plasma levels 236 
The effect of intragastric administration of DB on the release of motilin and ghrelin during the 237 
interdigestive state was measured. There was a significant main effect of treatment (Figure 238 
4A; p=0.04) on the percentage change of motilin plasma levels due to a relative increase in 239 
motilin plasma levels during placebo administration and a relative decrease during intragastric 240 
administration of DB. There was no difference between the 2 treatment arms for the 241 
percentage change of total (Figure 4B; p=0.3) or octanoylated (Figure 4C; p=0.5) ghrelin 242 
plasma levels. Values of the raw hormone plasma concentrations can be found in the online 243 
supplemental material (Supplemental Figure 2). 244 
The change in antral motility was affected by the change in motilin plasma levels (p=0.0003), 245 
as well as by DB administration (p=0.02) (Table 2). Furthermore, a significant interaction effect 246 
between these two factors was found (p=0.01). This interaction effect depicts a significant 247 
difference in the slope of the regression curves between placebo and DB. This positive 248 
assiciation between antral motility and motilin plasma levels was reduced after DB 249 
administration compared to placebo (Table 3). A similar result was obtained for the effect of 250 
motilin plasma level changes on changes in hunger ratings (Table 4). There was a significant 251 
main effect of motilin (p=0.0002), DB administration (p=0.02) and a significant interaction 252 
effect between the two (p=0.02). The slope of the regression curve between hunger changes 253 
and motilin changes differed between placebo and DB (Table 3).  254 
Changes in antral motility were not associated with changes in total (p=0.9) or octanoylated 255 
ghrelin (p=0.9) (Table 2). Changes in total ghrelin plasma levels showed a trend (p=0.06) to be 256 
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associated with changes in hunger ratings. There was no associaton between changes in 257 
octanoylated ghrelin (p=0.9) plasma levels and changes in hunger ratings (Table 4). 258 
Intragastric administration of DB suppresses hunger and increases satiety ratings after a meal 259 
DB administration before the standard meal was associated with prolonged elevated satiety 260 
scores and delayed return of hunger after the meal (Figure 5). Hunger scores (Figure 5A) were 261 
affected by both DB administration (main effect with lower ratings over all time points after 262 
DB, p=0.008) and time relative to the meal (p<0.0001). The course of hunger over time tended 263 
to differ between placebo and bitter adminsitration (p=0.07). Similarly, satiety scores (Figure 264 
5B) were affected by both DB administration (higher ratings over all time points after DB, 265 
p=0.01) and time (p<0.0001). There was no interaction effect between time and bitter 266 
administration for satiety scores (p=0.4). 267 
Gastric half-emptying time (measured in 6 subjects) did not differ between placebo and DB 268 
(109 [93, 118] min vs 109 [87, 128] min; p=0.7).  269 
Ad libitum food intake tended to decrease after intragastric administration of DB compared 270 
with placebo (720±58 kcal vs 796±45 kcal; p=0.08) (Figure 6). 271 
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DISCUSSION  272 
Our study showed that DB inhibited phase III contractions with gastric origin, with an 273 
increased occurrence of phase III starting in the duodenum. In keeping with a role for gastric 274 
phase III in determining interdigestive hunger, this switch was accompanied by a decrease in 275 
hunger scores (20). Similar to our findings in the lingual system, the response to DB was sex-276 
dependent, being more pronounced in women than in men. The increase in motilin plasma 277 
levels was significantly inhibited after DB administration compared to placebo, but ghrelin 278 
plasma levels were not affected. The positive association between motilin and antral motility 279 
was reduced after intragastric DB administration. A similar result was obtained for the 280 
association between motilin and hunger ratings. Moreover, our study showed that intragastric 281 
administration of DB decreased hunger and increased satiety scores after a standard meal 282 
without altering gastric emptying. Finally, ad libitum food intake tended to decrease after 283 
intragastric DB administration. 284 
The most characteristic property of DB is its extreme bitter taste (2). DB is known to interact 285 
with 8 of the bitter taste receptors in man (TAS2R4, TAS2R8, TAS2R10, TAS2R13, TAS2R39, 286 
TAS2R43, TAS2R46, TAS2R47) (31, 32). Our finding that women perceive a bitter lingual 287 
stimulus more intensely than men is in agreement with previous bitter sensitivity studies (6, 288 
8). This sex difference has been associated with the density of fungiform papillae on the 289 
anterior tongue and with polymorphisms in the haplotypes of the TAS2R38 gene for PROP 290 
sensitivity (6, 7, 33, 34).    291 
In addition we found that in women, but not in men, there was a switch in the origin of phase 292 
III contractions from the stomach to the duodenum after administration of DB. This occurred 293 
in parallel with a significant inhibition of hunger during phase III. The inhibitory effect of bitter 294 
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stimuli on antral motility and hunger has already been suggested in the beginning of the 295 
previous century by Carlson (22). A dose of 1 µmol/kg DB was chosen since this dosage 296 
significantly inhibited gastric accommodation without inducing adverse events (13). Also in 297 
the present study no adverse events were reported by the volunteers. Two chronic toxicity 298 
studies showed no significant changes in general behavior and appearance, ophthalmoscopy, 299 
electrocardiograms, body weight, hematological and biochemical studies or urinalysis (35-37). 300 
There is only one published case report of adverse reactions due to an allergic reaction after 301 
exposure to DB (38). Oral administration of 10 ppm DB to children aged 17-36 months induced 302 
a strong taste aversion, but no other effects were noted (1). 303 
It needs to be mentioned that the increase in hunger during phase III was weaker in male in 304 
comparison to female participants during placebo administration in the current study. One 305 
factor contributing to this difference in hunger changes could be the lower occurrence of 306 
gastric phase III contractions in male participants during the present study. Previous studies 307 
did not report a difference in association of phase III contractions and hunger ratings between 308 
men and women (20), but this aspect needs to be studied in more detail and in larger numbers 309 
in future research. 310 
Our study showed that only motilin plasma levels were decreased after administration of DB. 311 
A significant positive association was observed between antral motility and plasma motilin, 312 
but not ghrelin levels. This confirms our previous finding that motilin but not ghrelin is the key 313 
regulator of the MMC in man (19). After administration of DB, this association between motilin 314 
plasma levels and antral motility was reduced, but also the positive relationship between 315 
motilin plasma levels and hunger scores, confirming our recently published observation that 316 
motilin signals hunger (20). 317 
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It has already been described that taste receptors are expressed on enteroendocrine cells, 318 
allowing them to modulate the release of several gastrointestinal hormones (11, 12, 39-41). 319 
In mice, intragastric administration of DB (10 mM) significantly increased both total and 320 
octanoylated ghrelin levels during the first 30 min after gavage (10). Our results in humans 321 
differ as we showed no effect of intragastric DB on ghrelin plasma levels. Comparing the two 322 
studies is difficult due to species and sex differences and also differences in the dosage. The 323 
expression of bitter taste receptors on motilin-producing cells has not been reported but 324 
needs to be addressed. In addition, a direct effect of DB on smooth muscle cell contractility 325 
cannot be excluded since expression of bitter taste receptors has been shown on human 326 
gastric smooth muscle cells. DB administration induced Ca²+ rises and increased extracellular 327 
signal-regulated kinase (ERK) phosphorylation in human gastric smooth muscle cells (13). 328 
Furthermore, bitter compounds induced concentration and region-dependent contractility 329 
changes in mouse intestinal muscle strips (13). 330 
However, the current study does not rule out that the findings related to the administration 331 
of DB are mediated via a different pathway. Rogachevskaja et. al.(42) have shown that DB also 332 
binds to the extracellular Ca2+-sensing receptor (CASR). Moreover, this receptor is also 333 
expressed in the GIT and has been linked to acid secretion and nutrient sensing (43). Further 334 
studies are necessary to elucidate via which pathway DB exerts its effects. 335 
Finally, our study also showed that intragastric administration of DB delayed the return of 336 
hunger and prolonged the satiety feeling after a meal without affecting gastric emptying. 337 
Intragastric administration of DB in mice was able to delay gastric emptying, but the dosage 338 
used was 60 times higher (13). We already reported an effect of DB on satiation during an oral 339 
nutrient challenge test and on gastric accommodation in healthy volunteers (13). The effect 340 
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of DB on both hunger and satiety could be due to a combined effect on the release of both 341 
hunger and satiety hormones. In the present study, we have shown that motilin release is 342 
diminished after DB administration which affects hunger scores. Another study performed by 343 
Kim et. al.(11) showed that administration of DB in mice increased the secretion of GLP-1, a 344 
gastrointestinal hormone known to decrease food intake. Moreover it has been reported that 345 
intragastric administration of DB in mice activates neurons in the nucleus of the solitary tract 346 
possibly via the release of CCK and PYY (44). 347 
Few studies to date have evaluated the effect of bitter agonist administration on food intake 348 
in human volunteers. Our results showed a trend that DB administration decreased caloric 349 
intake. One study reported that intraduodenal administration of quinine (75 mg in 120 ml tap 350 
water) did not alter food intake (45). However, another study reported reduced food intake 351 
after intraduodenal administration of quinine (18 mg in an acid-resistant capsule) (23). These 352 
differences in outcomes are probably due to differences in compounds, administration routes, 353 
dosages and study design. The effect of these compounds on the release of anorexigenic and 354 
orexigenic hormones deserves further evaluation in larger subject groups, outside the scope 355 
of the present study, as this could lead to the development of new therapeutic approaches in 356 
the treatment of obesity. 357 
In summary, for the first time, we provide evidence that DB administered intragastrically is 358 
able to decrease both antral motility and hunger during the fasting state. These effects are 359 
probably caused by the inhibitory effect of DB on motilin release. Moreover, DB increased 360 
satiety and decreased hunger ratings after a standardized meal. These results suggest that DB, 361 
and potentially also other bitter tastants, could be investigated for their potential application 362 
for the treatment of obesity. 363 
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TABLES 
Table 1. Comparison of BMI and age between male and female participants 
 Men Women p-value 
BMI_study 1 
(kg/m²) 
24 [21, 26] (n=26) 22 [20, 24] (n=39) 0.02 
Age_study 1 (years) 25 [23, 33] (n=26) 26 [23, 32] (n=39) 0.9 
BMI_study 2 
(kg/m²) 
25±2 (n=10) 22±1 (n=10) 0.003 
Age_study 2 (years) 23 [22, 26] (n=10) 25 [22, 35] (n=10) 0.6 
Data are represented as mean±SEM or median [Q1, Q3]. BMI and age were compared 
between sexes using two-tailed unpaired Student’s t-test or Mann Whitney U test depending 
on the distribution. 
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Table 2. The effect of hormone plasma levels on antral motility (n=12) 
 Motilin Total ghrelin Octanoylated ghrelin 
Main effect hormone 0.0003 0.9 0.9 
Main effect administration 0.02 0.8 0.2 
Main effect time 0.1 0.1 0.1 
Hormone by administration 0.01 0.7 0.2 
Data were analyzed using mixed model analysis. Antral motility was the dependent variable. 
The hormone of interest (motilin, total or octanoylated ghrelin), administration, time and an 
interaction effect between hormone and administration were the independent variables. The 
table depicts the calculated p-values. 
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Table 3. The interaction effect between motilin and intragastric administration on antral 
motility and hunger 
 Placebo (n=12) DB (n=12) 
Antral motility 238±46 45±77* 
Hunger 6.22±1.2 1.33±2.0* 
Values represent betas, which are the slopes of the regression curves. *: p<0.05 vs placebo. 
Bèta values are given as mean±SEM. 
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Table 4. The effect of hormone plasma levels on hunger scores (n=12) 
 Motilin Total ghrelin Octanoylated ghrelin 
Main effect hormone 0.0002 0.06 0.9 
Main effect administration 0.02 0.3 0.3 
Main effect time 0.5 0.6 0.3 
Hormone by administration 0.02 0.3 0.4 
Data were analyzed using mixed model analysis. Hunger was the dependent variable. The 
hormone of interest (motilin, total or octanoylated ghrelin), administration, time and an 
interaction effect between hormone and administration were the independent variables. The 
table depicts the calculated p-values.  
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FIGURE LEGENDS 
Figure 1. Schematic overview of the protocol outline. All protocols were single-blinded 
randomized placebo-controlled trials. Either placebo (water) or DB (1 µmol/kg 
bodyweight) were administered intragastrically using a nasogastric feeding tube. 
Antroduodenal motility was measured continuously during the course of both study 2 
and 3 with high-resolution manometry. Hunger and satiety ratings were scored on 
10cm visual analog scales with endpoints. Blood samples were collected via an i.v. 
catheter and analyzed using hormone-specific RIAs to measure motilin and ghrelin 
(total and octanoylated) plasma levels. Pancakes were labeled with sodium 13C-
octanoate to assess gastric half-emptying time.   
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Figure 2. Bitter lingual sensitivity in male and female participants. These data are part of 
study protocol 1. 6 different concentrations of DB were scored for their bitterness 
using taste strips. Concentrations were presented in ascending order and placed on 
the tongue for 90 sec. Participants rinsed their mouth between consecutive 
administrations. Bitter taste perception was scored on a 10-cm visual analog scale. The 
data was analyzed using mixed-model analysis, with bitter scores as the dependent 
variable and sex, concentration (repeated statement), BMI and an interaction effect 
between sex and concentration as the independent variables. Both DB concentration 
(p<0.0001) and sex (p=0.005) had a significant effect on bitter taste perception. There 
was no significant effect of BMI (p=0.06) or a significant interaction effect between sex 
and DB concentration (p=0.1). Data are represented as means and SEMs.  
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Figure 3. Origin of phase III and hunger scores after intragastric administration of DB (1 
µmol/kg). These data are part of study protocol 2. Percentage of phase III with gastric 
and duodenal origin after intragastric administration of placebo or 1 µmol/kg DB in (A) 
female and (B) male participants. McNemar’s test was used to compare the origin 
between both conditions (*: p<0.05). Percentage change in hunger scores during phase 
III for (C) female and (D) male participants. Percentage change of hunger was 
calculated with 10 min prior to intragastric administration as the reference point. The 
data was analyzed with mixed-model analysis. Percentage change of hunger scores was 
the dependent variable and time, drug and an interaction effect between drug and 
condition were the independent variables. Both drug and time were entered as 
repeated categorical variables. In females the percentage change of hunger scores 
differed significantly between placebo and DB administration (p=0.04), there was no 
significant time (p=07) or interaction effect (p=0.9). In men there was no significant 
effect of condition (p=0.3) or a significant interaction effect (p=0.3), but there was a 
significant time effect (p=0.04). Data (C and D) are represented as means and SEMs.  
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Figure 4. The effect of intragastric administration of DB on motilin and ghrelin plasma levels. 
These data are part of study protocol 3. Percentage change of (A) motilin, (B) total and 
(C) octanoylated ghrelin plasma levels after intragastric administration of placebo or 1 
µmol/kg DB. Time point 0 indicates the start of the intragastric administration. 
Percentage change of the hormone levels was calculated with 10 min prior to 
intragastric administration as the reference point. *: p<0.05. The data was analyzed 
with mixed-model analysis. Change in plasma concentration of the hormone of interest 
was the dependent variable and time, drug and an interaction effect between drug and 
condition were the independent variables. Both drug and time were entered as 
repeated categorical variables. Change in motilin plasma levels differed significantly 
between placebo and DB administration (p=0.04) there was no significant time (p=0.3) 
or interaction effect (p=0.07). There was no significant main effect of drug 
administration (p=0.3) or time (p=0.2) and no significant interaction effect (p=0.3) for 
total ghrelin plasma levels. There was no significant main effect of drug administration 
(p=0.5) or time (p=0.5) and no significant interaction effect (p=0.2) for octanoylated 
ghrelin plasma levels. Data are represented as means and SEMs.  
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Figure 5. The effect of intragastric administration of DB on hunger and satiety scores after a 
meal. These data are part of study protocol 4. (A) Hunger and (B) satiety scores after 
placebo or 1 µmol/kg DB intragastric administration. Compounds were administered 
30 min before the start of the meal (500 kcal). Time point 0 indicates start of meal 
intake. *: p<0.05 Data was analyzed with mixed-model analysis. Hunger or satiety 
scores were the dependent variables and time, drug and an interaction effect between 
drug and condition were the independent variables. Both drug and time were entered 
as repeated categorical variables. Both hunger and satiety scores were significantly 
affected by time (both p<0.0001) and drug administration (p=0.008 and p=0.01 
respectively). There was no significant interaction effect between time and drug 
administration for hunger (p=0.07) and satiety (p=0.4) scores. Data are represented as 
means and SEMs.  
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Figure 6. Food intake after intragastric administration of DB.  These data are part of study 
protocol 5. Caloric intake was calculated in kcal. Total caloric value of the excess-choice 
buffet meal was 4211 kcal. DB (1 µmol/kg) or placebo were given intragastrically 40 
min prior to the start of the buffet meal. Subjects had 1 hour to eat ad libitum. Caloric 
intake between placebo and DB administration was compared using a one-tailed 
paired Student’s t-test (p=0.08). 
